BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Chan HLY, Dan YY, Lee MH, Lim YS, Kruger E, Tan SC. Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. J Viral Hepat. 2018;25:228-235. [PMID: 29053909 DOI: 10.1111/jvh.12808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Vergara M, Miquel M, Vela E, Cleries M, Pontes C, Prat A, Rué M. Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents. J Viral Hepat 2021;28:728-38. [PMID: 33555102 DOI: 10.1111/jvh.13479] [Reference Citation Analysis]
2 Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 [PMID: 31183003 DOI: 10.4254/wjh.v11.i5.421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Scott DN, Palmer MA, Tidhar MT, Stoove PM, Sacks-Davis DRS, Doyle AJS, Pedrana DAJ, Thompson PA, Wilson PDP, Hellard PM. Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. Lancet Reg Health West Pac 2022;18:100316. [PMID: 35024654 DOI: 10.1016/j.lanwpc.2021.100316] [Reference Citation Analysis]
4 Younossi ZM, Golabi P, Henry L. A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. Journal of Clinical Gastroenterology 2019;53:331-41. [DOI: 10.1097/mcg.0000000000001179] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
5 Lim AG, Scott N, Walker JG, Hamid S, Hellard M, Vickerman P. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. PLoS Med 2021;18:e1003818. [PMID: 34665815 DOI: 10.1371/journal.pmed.1003818] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kim DY, Wong G, Lee J, Kim MH, Smith N, Blissett R, Kim HJ. Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea. Curr Med Res Opin 2020;36:993-1002. [PMID: 32295431 DOI: 10.1080/03007995.2020.1756232] [Reference Citation Analysis]
7 Mallolas J, Ahumada A, Ampuero J, Blanco JR, Hidalgo Á, Londoño MC, Molina E, Ruiz S. Quality of life in patients with hepatitis C. Importance of treatment. Gastroenterol Hepatol 2019;42 Suppl 1:20-5. [PMID: 32560769 DOI: 10.1016/S0210-5705(20)30184-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Scott N, Kuschel C, Pedrana A, Schroeder S, Howell J, Thompson A, Wilson DP, Hellard M. A model of the economic benefits of global hepatitis C elimination: an investment case. Lancet Gastroenterol Hepatol 2020;5:940-7. [PMID: 32730785 DOI: 10.1016/S2468-1253(20)30008-X] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]